Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 5 | 2017 | 50 | 1.010 |
Why?
|
| General Surgery | 2 | 2013 | 36 | 0.440 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2017 | 23 | 0.430 |
Why?
|
| Aptitude Tests | 1 | 2013 | 2 | 0.430 |
Why?
|
| Genetic Therapy | 2 | 2013 | 75 | 0.420 |
Why?
|
| Ileal Neoplasms | 1 | 2011 | 2 | 0.370 |
Why?
|
| Skin Neoplasms | 2 | 2013 | 72 | 0.370 |
Why?
|
| Clinical Competence | 1 | 2013 | 184 | 0.370 |
Why?
|
| Herpesvirus 1, Human | 1 | 2010 | 2 | 0.340 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 18 | 0.340 |
Why?
|
| Laparoscopy | 1 | 2011 | 137 | 0.330 |
Why?
|
| Genetic Vectors | 1 | 2010 | 51 | 0.330 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 307 | 0.310 |
Why?
|
| Rosaniline Dyes | 1 | 2008 | 2 | 0.300 |
Why?
|
| Radioisotopes | 1 | 2008 | 13 | 0.300 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 77 | 0.300 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 337 | 0.230 |
Why?
|
| Immunotherapy | 2 | 2013 | 49 | 0.210 |
Why?
|
| Cancer Vaccines | 2 | 2012 | 3 | 0.180 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2012 | 36 | 0.180 |
Why?
|
| Humans | 13 | 2017 | 22848 | 0.150 |
Why?
|
| Sentinel Lymph Node | 1 | 2017 | 1 | 0.140 |
Why?
|
| Watchful Waiting | 1 | 2017 | 8 | 0.140 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 20 | 0.140 |
Why?
|
| Opioid-Related Disorders | 1 | 2017 | 39 | 0.130 |
Why?
|
| Clinical Clerkship | 2 | 2013 | 25 | 0.130 |
Why?
|
| Animals | 6 | 2013 | 3025 | 0.130 |
Why?
|
| Pain Management | 1 | 2017 | 125 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2017 | 116 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2017 | 361 | 0.130 |
Why?
|
| Adult | 5 | 2017 | 6584 | 0.120 |
Why?
|
| Lymph Nodes | 2 | 2017 | 61 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2017 | 3062 | 0.120 |
Why?
|
| Gastroscopy | 1 | 2015 | 7 | 0.120 |
Why?
|
| Gastrostomy | 1 | 2015 | 7 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2017 | 210 | 0.120 |
Why?
|
| Patient Safety | 1 | 2015 | 29 | 0.110 |
Why?
|
| Middle Aged | 5 | 2017 | 7555 | 0.110 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2015 | 59 | 0.110 |
Why?
|
| Animals, Laboratory | 1 | 2013 | 2 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 1 | 2015 | 134 | 0.100 |
Why?
|
| Hypopigmentation | 1 | 2013 | 2 | 0.100 |
Why?
|
| Vitiligo | 1 | 2013 | 3 | 0.100 |
Why?
|
| Mutant Proteins | 1 | 2013 | 6 | 0.100 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2013 | 7 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 26 | 0.100 |
Why?
|
| Autoimmunity | 1 | 2013 | 10 | 0.100 |
Why?
|
| Education, Medical | 1 | 2013 | 44 | 0.100 |
Why?
|
| Students, Medical | 1 | 2013 | 56 | 0.100 |
Why?
|
| Immunotherapy, Active | 1 | 2012 | 1 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 155 | 0.090 |
Why?
|
| Laparoscopes | 1 | 2011 | 1 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 62 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 99 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 305 | 0.090 |
Why?
|
| Defective Viruses | 1 | 2010 | 1 | 0.090 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2010 | 2 | 0.090 |
Why?
|
| Mice | 2 | 2013 | 1128 | 0.090 |
Why?
|
| Injections, Intralesional | 1 | 2010 | 30 | 0.080 |
Why?
|
| Virus Replication | 1 | 2010 | 34 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2010 | 51 | 0.080 |
Why?
|
| Male | 6 | 2017 | 12453 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2010 | 122 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2015 | 2960 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2013 | 1528 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 95 | 0.080 |
Why?
|
| Patient Selection | 1 | 2010 | 157 | 0.080 |
Why?
|
| Research Design | 1 | 2010 | 147 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2010 | 106 | 0.080 |
Why?
|
| Drug Hypersensitivity | 1 | 2008 | 6 | 0.080 |
Why?
|
| Coloring Agents | 1 | 2008 | 11 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 110 | 0.070 |
Why?
|
| Aged | 4 | 2017 | 7669 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 208 | 0.070 |
Why?
|
| Linear Models | 1 | 2008 | 205 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 588 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2011 | 280 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 401 | 0.070 |
Why?
|
| Female | 5 | 2017 | 12677 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 1494 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2008 | 485 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2008 | 1621 | 0.050 |
Why?
|
| Young Adult | 2 | 2017 | 1721 | 0.050 |
Why?
|
| Vaccines, DNA | 2 | 2012 | 3 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 177 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2017 | 819 | 0.040 |
Why?
|
| Pain Clinics | 1 | 2017 | 4 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 4055 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 5 | 0.030 |
Why?
|
| Lymphedema | 1 | 2017 | 4 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 259 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 138 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 81 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 210 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 108 | 0.030 |
Why?
|
| Palliative Care | 1 | 2017 | 94 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 270 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2017 | 205 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 630 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2013 | 31 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 4 | 0.030 |
Why?
|
| Antigens | 1 | 2013 | 8 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 90 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2013 | 23 | 0.030 |
Why?
|
| Vaccination | 1 | 2013 | 26 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2013 | 101 | 0.030 |
Why?
|
| Forecasting | 1 | 2013 | 85 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 51 | 0.030 |
Why?
|
| Transfection | 1 | 2013 | 104 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 92 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 44 | 0.030 |
Why?
|
| Disease Management | 1 | 2013 | 82 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 81 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 149 | 0.020 |
Why?
|
| Anxiety | 1 | 2013 | 107 | 0.020 |
Why?
|
| Skin | 1 | 2013 | 113 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2012 | 5 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 254 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 25 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 343 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2013 | 191 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 226 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 554 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 96 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 977 | 0.020 |
Why?
|
| United States | 1 | 2013 | 1726 | 0.020 |
Why?
|